<DOC>
	<DOCNO>NCT01296256</DOCNO>
	<brief_summary>The purpose study determine whether Bendamustine combination Etoposide , Cytarabine Melphalan ( BeEAM ) effective conditioning follow ASCT patient aggressive lymphoma .</brief_summary>
	<brief_title>Bendamustine , Cytarabine , Etoposide Melphalan ( BeEAM ) Conditioning Autologous Stem Cell Transplant ( ASCT ) Aggressive Non Hodgkin 's Lymphoma ( NHL ) .</brief_title>
	<detailed_description>BCNU ( carmustine nitrosurea alkylating agent use many year condition patient lymphoma however drug hardly available country Europe , moreover improve conditioning regimen autologous stem cell transplant important anti-tumoral effect high dose therapy responsible procedure efficacy . Although many year advance achieve area new drug test patient . Bendamustine unique cytotoxic agent structural similarity alkylating agent antimetabolite , non-cross-resistant alkylating agent drug vitro clinic . Early clinical study conduct German Democratic Republic 30 year ago suggest promising activity indolent non-Hodgkin 's lymphoma ( NHL ) . Two North American trial report response 70 % patient chemotherapy- rituximab-refractory disease , suggest bendamustine may effective drug available patient population . Response rate 90 % 92 % , complete remission 55 % 60 % , report patient follicular mantle-cell lymphoma combination bendamustine rituximab . ( Cheson 2009 ) Leone et recently report result characterization mechanisms action bendamustine comparison structurally related compound chlorambucil phosphoramide mustard demonstrated bendamustine display distinct mechanisms action include activation DNA-damage stress response apoptosis , inhibition mitotic checkpoint , induction mitotic catastrophe . Also bendamustine activates base excision DNA repair pathway rather alkyltransferase DNA repair mechanism . These data suggest bendamustine posse mechanistic feature differentiate alkylating agent make old new drug attractive one combine agent condition transplant setting ( Leone 2008 ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Patients able meet requirement clinical trial , accord investigator 's criterion , 2 . Patient give voluntarily write informed consent perform essay test part routine care patient . 3 . Age &gt; o=18 year &gt; 0=70 year 4 . Candidate chemotherapy ( QT ) high dos ASCT 1 . Histologically confirm aNHL : 2 . Patients DLBCL grade 3 b Follicular lymphoma PTCL ( include anaplastic ALK + ) sensitive relapse , , second complete partial response , minimum 2 cycle rescue regimen . 3 . Patients DLBCL grade 3 b Follicular lymphoma PTCL ( include anaplastic ALK + ) first complete partial response , one treatment line require reach first complete partial response . 4 . Transformed B cell lymphoma first CR 5 . Patients PTCL ( anaplastic ALK + ) first CR 5 . Performance status ( ECOG ) &lt; 0=2 . 6 . Adequate renal , hepatic , bone marrow function ( assessed &lt; 14 day initiation study treatment ) : 1 . Neutrophil count &lt; o=1.5 x 109/L 2 . Platelet count &lt; o=100 x 109/L 3 . Haemoglobin &lt; o=8.0 g/dL 4 . Creatinine serum &gt; o=1,5 x ULN mg/dl 5 . Serum bilirubin &lt; o=1.5 x ULN alkaline phosphatase &lt; o=2.5 x ULN 6 . AST , ALT &lt; o=2.5 x ULN ( &lt; o=5 x ULN case liver metastasis ) . 7 . Adequate pulmonary function : forced expiratory volume 1 second &gt; 65 % predict diffusing capacity lung CO &gt; o=50 % . 8 . Cardiac ejection fraction great 50 % echocardiogram FEVI . 9 . A woman capable gestation ( see definition ) : Have two medically supervise negative pregnancy test ( minimum sensitivity 25 mIU / ml ) start study therapy ( first pregnancy test complete 10 14 day prior initiate bendamustine latter pregnancy test 24 hour start drug ) . Commit continue abstinence heterosexual relationship agree use reliable contraception without interruption , 28 day start study therapy , study therapy 28 day stop therapy study . A woman capable gestation define sexually mature woman : 1. undergone hysterectomy bilateral oophorectomy 2. naturally postmenopausal ( amenorrhea result cancer treatment rule reproductive potential ) least 24 consecutive month ( i.e. , menses time previous 24 consecutive month ) . 1 . Impossibility collecting , via apheresis , number CD34+ cell &gt; o=2 x 106/kg 2 . To receive follow treatment 28 day start study treatment : i.chemotherapeutic antitumor agent ii.radiation therapy , except limited field , maximum dose &lt; o=10 Gy control serious lifethreatening symptom iii.glucocorticoids , except dos equivalent &lt; o=1 mg / kg prednisolone / day duration &lt; o=7 day iv.any therapeutic agent investigation . 3 . Known involvement central nervous system ( CNS ) lymphoma 4 . Abnormalities cardiac function clinically significant heart disease acute myocardial infarction unstable angina within 6 month prior start study treatment , heart failure NYHA class III IV , uncontrolled hypertension history antihypertensive treatment poor compliance , uncontrolled arrhythmia treatment , except extrasystole minor conduction disorder . 5 . Other serious uncontrolled medical condition , uncontrolled diabetes , uncontrolled active infection , significant cerebrovascular disease poorly control psychiatric disease . 6 . Known suspected hypersensitivity agent excipients regime evaluation . 7 . Presence limitation compromise patient 's ability comply study treatment . 8 . Positive serology HIV , HCV HBV surface antigen ( HBsAg ) . If HBsAg negative anticore antibody ( HBcAb ) positive antibody surface antigen ( HBsAb ) negative , HBV DNA test ; If positive result patient may include trial . If types antibody HBcAb HBsAb positive ( indicative past infection ) , patient may include study . 9 . Previous history malignancy lymphoma ( except basal cell squamous cell skin carcinoma carcinoma situ cervix breast ) unless patient free disease beyond 5 year . 10 . Major surgery procedure within 30 day prior enter study . 11 . Pregnant nursing female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Bendamustine</keyword>
	<keyword>Conditioning Therapy</keyword>
	<keyword>Autologous Stem Cell Transplant</keyword>
	<keyword>Aggressive Non Hodgkin 's Lymphoma</keyword>
</DOC>